Latest news with #VeevaMedTech
Yahoo
2 days ago
- Business
- Yahoo
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed PLEASANTON, Calif., June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from Veeva MedTech. With a growing number of medical device and diagnostic clinical trials executed on Veeva Clinical applications, companies can gain the scalability to grow while maintaining compliance with local, regional, and global regulations. Medtechs of all sizes use Veeva to drive improvements, with customers achieving 50% faster study build times with Veeva EDC and 80% reductions in duplicate trial documents with Veeva eTMF. "It's exciting to partner with the industry as it moves to Veeva MedTech for a complete and connected medical device and diagnostics clinical trials infrastructure," said Kevin Liang, vice president of clinical strategy at Veeva MedTech. "We're working with leading medtechs to advance study execution, collaboration, and innovation to bring life-changing products to patients faster." What the medtech clinical industry is saying about Veeva: "With Veeva EDC, we've partnered closely with their team to enhance the global library and develop reusable standards.," said Leianne Ebert, head of clinical data operations at Alcon. "We focused on getting standards right, and that commitment drove 50% standardization in one year, boosting our compliance with our global library." "Veeva allows us to collect study data consistently in a manner that regulatory agencies will accept," said Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health. "Whether it's a registry study or an IDE/IND study supporting a PMA/BLA, the data's going to be collected the exact same way and in a compliant manner." "Since implementing Veeva eTMF, we've reduced our quality control time by over 90% and decreased our document creation times significantly," said Matt Christensen, senior vice president, global clinical and medical affairs at Smith+Nephew. Learn more about Veeva Clinical Platform applications for medtech at About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact:Deivis MercadoVeeva View original content to download multimedia: SOURCE Veeva Systems Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed PLEASANTON, Calif., June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from Veeva MedTech. With a growing number of medical device and diagnostic clinical trials executed on Veeva Clinical applications, companies can gain the scalability to grow while maintaining compliance with local, regional, and global regulations. Medtechs of all sizes use Veeva to drive improvements, with customers achieving 50% faster study build times with Veeva EDC and 80% reductions in duplicate trial documents with Veeva eTMF. "It's exciting to partner with the industry as it moves to Veeva MedTech for a complete and connected medical device and diagnostics clinical trials infrastructure," said Kevin Liang, vice president of clinical strategy at Veeva MedTech. "We're working with leading medtechs to advance study execution, collaboration, and innovation to bring life-changing products to patients faster." What the medtech clinical industry is saying about Veeva: "With Veeva EDC, we've partnered closely with their team to enhance the global library and develop reusable standards.," said Leianne Ebert, head of clinical data operations at Alcon. "We focused on getting standards right, and that commitment drove 50% standardization in one year, boosting our compliance with our global library." "Veeva allows us to collect study data consistently in a manner that regulatory agencies will accept," said Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health. "Whether it's a registry study or an IDE/IND study supporting a PMA/BLA, the data's going to be collected the exact same way and in a compliant manner." "Since implementing Veeva eTMF, we've reduced our quality control time by over 90% and decreased our document creation times significantly," said Matt Christensen, senior vice president, global clinical and medical affairs at Smith+Nephew. Learn more about Veeva Clinical Platform applications for medtech at About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact:Deivis MercadoVeeva View original content to download multimedia: SOURCE Veeva Systems
Yahoo
4 days ago
- Business
- Yahoo
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years
Industry focused on automation, connectivity, and reporting for proactive quality management PLEASANTON, Calif., June 9, 2025 /PRNewswire/ -- The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality management within the next three years to improve compliance and drive innovation. This signals a shift toward modernization to reduce risk and foster a stronger culture of quality across the product lifecycle. While the move to more scalable solutions is planned or underway for most, 68% of medtechs currently rely on manual processes, a mix of paper-based and electronic systems, or legacy on-premise solutions. This can cause delays in addressing product issues and lead to backlogs in complaint handling. Companies with slow response times to patient safety concerns incur significant risks in compliance, consumer trust, and brand reputation. The research highlights opportunities for medtechs to streamline quality operations for proactive management and execution, including: An emphasis on proactive action. The primary drivers to advance quality are proactive and risk-based quality management (38%) and scaling processes to support growth (26%) to adapt to market changes. Technology viewed as an enabler. With more than half of medtechs working on manual processes, most respondents say advanced technology can drive automation for faster timelines and efficiency (75%), connections with other quality management system processes (62%), and advanced reporting for data-driven decision-making (61%). Generative AI, intelligent automation, and robotic process automation scarcely adopted. Less than 3% of companies have reliably applied these emerging technologies across their organizations. Despite limited adoption, there is strong optimism about the potential of these technologies, with improving timeliness and efficiency ranked as the top opportunities. Gaps in employee training exist. Only 19% of respondents say their training programs are sufficient to support postmarket quality teams for future success. This presents an opportunity to introduce an interactive learning approach that ensures employees receive real-time updates and guidance on job responsibilities. "While initiatives are underway to simplify and connect medtech quality operations, the research reveals that many of the organizations surveyed are limited by legacy systems and manual processes," said Vishaka Rajaram, senior director of quality strategy at Veeva MedTech. "By aligning strategic goals with modern technology solutions, medtechs can move from reactive issue management to proactive risk prevention for greater speed and compliance." The 2025 Veeva MedTech Postmarket Quality Benchmark Report surveyed more than 100 quality medtech leaders, examining the medical device and diagnostic industry's progress, challenges, and opportunities in quality management. To learn more, read the benchmark report here. About Veeva SystemsVeeva (NYSE: VEEV) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Contact:Deivis MercadoVeeva View original content to download multimedia: SOURCE Veeva Systems Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
